First-Line and Second-Line T Cell Lymphoma Treatments

T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for most subtypes of T cell lymphoma because T cell lymphomas are relatively rare, representing about 15% of all non-Hodgkin's lymphomas diagnosed annually. Many T cell lymphoma subtypes, perhaps a majority, have a relatively poor prognosis with or without T cell lymphoma treatment.

First-Line T Cell Lymphoma Treatment

First-line therapeutic intervention for cases of noncutaneous peripheral T cell lymphomas remains relatively poorly explored, but some chemotherapy regimens are advocated in widely published T cell lymphoma treatment guidelines, such as:

  • CHOP (cyclophosphamide, vincristine, doxorubucin and prednisone)
  • DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin)
  • HyperCVAD (doxorubicin, vincristine, cyclophosphamide and dexamethasone)
  • High dose chemotherapy followed by a stem cell transplantation

Some T cell lymphoma patients may be guided towards a clinical trial as first-line therapy, depending on the diagnosis, staging, and other factors.

Second-Line T Cell Lymphoma Treatment

Second-line therapies for T cell lymphoma treatment include the following combination chemotherapy regimens, provided the patient is a candidate for stem cell transplantation:

  • DHAP (dexamethasone, cisplatin and cytarabine)
  • ESHAP (etopiside, methylprednisolone, cytarabine and cisplatin)
  • GDP (gemcitabine, dexamethasone and cisplatin
  • ICE (ifosfamide, carboplatin, etoposide)
  • MINE (mesna, ifosfamide, mitoxantrone and etoposide
  • Pralatrexate
  • GemOx (gemcitabine and oxaliplatin)

Similar to first-line options, for some patients referral to a clinical trial may constitute second-line therapy.

If the patient is not a candidate for stem cell transplantation, possible second-line therapies include the following:

  • Alemtuzumab
  • Bortezomib
  • Denileukin diftitox
  • Gemcitabine
  • Pralatrexate
  • Radiation

T cell lymphoma treatment options for less common T cell lymphoma subtypes, such as Adult T cell Leukemia/Lymphoma, as well as for cutaneous T cell lymphomas, will differ from what is presented here.

Source: National Comprehensive Cancer Network, Practice Guidelines in Oncology v.1., Peripheral T-Cell Lymphomas
Photo: Pexels

More Articles

More Articles is pleased to have the Lymphoma Information Network in the family of associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics


At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...